Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.59 | — | — | — | 120.76 | — | — | 7.60 | — | — | 12.11 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.83 | 14.46 | 13.74 | 11.68 | 2.03 | 2.29 | 2.91 | 3.54 | 3.27 | 5.21 | 15.08 | 195.22 | 141.65 | 153.60 | 178.60 | 1.51 | 148.14 | 24.44 | 30.99 | 7.56 | 17.25 |
| — | +530.0% | +371.5% | +229.7% | -37.9% | -56.0% | -80.7% | -98.2% | -97.7% | -96.6% | -91.6% | +12858.2% | -4.4% | +528.5% | +476.3% | -80.1% | +758.8% | +55.3% | +266.3% | -63.5% | -45.8% | |
| P/B Ratio | 1.36 | 7.35 | 5.32 | 6.40 | 2.85 | 1.58 | 1.07 | 1.37 | 1.64 | 1.13 | 3.02 | 2.61 | 1.15 | 1.13 | 0.82 | 0.76 | 0.72 | 0.71 | 1.02 | 1.56 | 2.19 |
| — | +365.2% | +397.6% | +365.3% | +73.6% | +39.8% | -64.6% | -47.3% | +42.1% | -0.2% | +266.0% | +242.8% | +61.1% | +60.2% | -19.0% | -51.3% | -67.3% | -69.6% | -66.0% | -58.1% | -9.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | 0.82 | — | 1.40 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | 6.25 | — | — | — | — | — | — | — | — | — | — | 1.30 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 30.27 | — | — | 3.85 | — | — | 8.52 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.6% | 15.6% | 21.5% | 71.2% | 93.3% | 85.5% | 81.1% | 80.2% | 82.8% | 81.0% | 48.2% | 41.0% | -16.8% | 69.1% | -140.3% | 95.7% | -108.5% | 74.8% | 76.9% | 81.6% | -10.9% |
| — | -81.7% | -73.5% | -11.3% | +12.7% | +5.5% | +68.2% | +95.7% | +593.4% | +17.2% | +134.4% | -57.1% | +84.5% | -7.6% | -282.5% | +17.3% | -898.8% | +1544.0% | +12.8% | +370.0% | +59.1% | |
| Operating Margin | -45.3% | -487.4% | -467.4% | -166.9% | 22.9% | -57.3% | -133.1% | -84.0% | -66.5% | -213.5% | -461.4% | -10451.9% | -13336.1% | -13291.6% | -16856.8% | 80.6% | -15541.5% | -2091.3% | -1754.4% | -253.4% | -509.8% |
| — | -750.3% | -251.2% | -98.7% | +134.4% | +73.2% | +71.2% | +99.2% | +99.5% | +98.4% | +97.3% | -13071.4% | +14.2% | -535.6% | -860.8% | +131.8% | -2948.7% | -523.6% | -2156.2% | +7.7% | -7.3% | |
| Net Margin | -92.7% | -417.3% | -307.5% | -253.2% | 1.7% | -141.9% | -170.1% | 46.6% | -142.3% | -313.5% | 124.6% | -15145.6% | -11278.7% | -5982.0% | -21636.0% | -168.5% | -16174.4% | -1450.7% | -1915.4% | -204.8% | -450.2% |
| — | -194.0% | -80.7% | -643.6% | +101.2% | +54.7% | -236.5% | +100.3% | +98.7% | +94.8% | +100.6% | -8886.4% | +30.3% | -312.4% | -1029.6% | +17.7% | -3493.0% | -306.1% | -4031.8% | +27.8% | +8.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -65.3% | -43.2% | -26.3% | -29.8% | 0.6% | -22.3% | -14.7% | 4.5% | -16.6% | -21.1% | 6.4% | -53.3% | -20.2% | -9.8% | -24.4% | -19.7% | -17.5% | -9.9% | -14.5% | -10.0% | -13.3% |
| — | -93.9% | -79.0% | -756.3% | +103.6% | -5.3% | -327.7% | +108.5% | +18.1% | -115.4% | +126.4% | -169.9% | -16.0% | +0.7% | -68.1% | -97.0% | -31.7% | +26.7% | -266.2% | +19.3% | -46.9% | |
| ROA | -19.1% | -7.8% | -5.8% | -7.9% | 0.2% | -6.6% | -4.8% | 1.5% | -5.7% | -6.6% | 1.6% | -15.8% | -8.0% | -4.4% | -11.7% | -9.9% | -9.5% | -5.7% | -8.8% | -6.3% | -8.6% |
| — | -18.4% | -19.8% | -618.7% | +102.9% | +0.4% | -395.9% | +109.6% | +28.2% | -49.3% | +114.0% | -58.9% | +15.7% | +21.6% | -34.1% | -57.7% | -10.3% | +36.0% | -236.3% | +24.0% | -35.9% | |
| ROIC | -23.5% | -17.1% | -15.3% | -9.5% | 4.4% | -6.8% | -13.3% | -11.4% | -10.6% | -16.9% | -33.0% | -35.4% | -16.2% | -16.8% | -15.8% | 8.2% | -15.3% | -13.6% | -14.2% | -15.1% | -20.2% |
| — | -152.2% | -14.8% | +16.1% | +141.7% | +60.0% | +59.7% | +67.9% | +34.5% | -0.5% | -109.7% | -533.0% | -5.6% | -24.1% | -10.9% | +154.0% | +24.3% | +16.5% | -71.5% | +8.2% | -52.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.58 | 2.06 | 1.81 | 1.58 | 0.92 | 0.98 | 0.79 | 0.70 | 0.71 | 0.61 | 1.04 | 1.00 | 1.10 | 0.91 | 0.62 | 0.60 | 0.66 | 0.52 | 0.54 | 0.43 | 0.39 |
| — | +111.0% | +129.5% | +126.3% | +30.6% | +59.0% | -24.1% | -30.5% | -35.6% | -32.2% | +69.1% | +66.9% | +65.3% | +74.0% | +14.5% | +41.0% | +68.4% | +49.0% | +50.1% | +23.5% | +19.6% | |
| Debt / EBITDA | — | — | — | — | 7.11 | — | — | — | — | — | — | — | — | — | — | 4.80 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.62 | 1.37 | 1.52 | 1.62 | 1.49 | 1.38 | 1.67 | 1.73 | 1.78 | 1.92 | 1.63 | 1.50 | 2.20 | 2.69 | 2.27 | 2.28 | 2.65 | 3.17 | 3.73 | 4.57 | 4.75 |
| — | -0.8% | -9.0% | -6.1% | -16.2% | -28.1% | +2.7% | +15.0% | -19.0% | -28.9% | -28.3% | -34.2% | -17.0% | -15.0% | -39.1% | -50.0% | -44.4% | -41.9% | -35.8% | -24.7% | -22.1% | |
| Quick Ratio | 1.62 | 1.37 | 1.52 | 1.62 | 1.49 | 1.38 | 1.67 | 1.73 | 1.78 | 1.92 | 1.63 | 1.50 | 2.20 | 2.69 | 2.27 | 2.28 | 2.65 | 2.62 | 3.73 | 4.57 | 4.72 |
| — | -0.8% | -9.0% | -6.1% | -16.2% | -28.1% | +2.7% | +15.0% | -19.0% | -28.9% | -28.3% | -34.2% | -17.0% | +2.7% | -39.1% | -50.0% | -44.0% | -51.4% | -34.5% | -24.3% | -21.3% | |
| Interest Coverage | -7.39 | -12.65 | -11.95 | -12.15 | 1.28 | -10.41 | -8.49 | 4.88 | -9.87 | -12.89 | 4.01 | -3.51 | -9.77 | -20.11 | -4.98 | — | -26.53 | -18.52 | -19.85 | -3.39 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLLS stock.
Cellectis S.A.'s current P/E is -1.6x. The average P/E over the last 1 quarters is 120.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cellectis S.A.'s current operating margin is -45.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cellectis S.A.'s business trajectory between earnings reports.